Lenvima®

 

Active substance Lenvatinib
Holder Eisa Ltd.
Status Closed
Indication Lenvatinib’s indication is the treatment of radioiodine-refractory differentiated thyroid cancer.
Public documents Approbation
Information for the patient
Informed consent
Last update 03/05/2018
Last updated on 13/02/2024